Journal article
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Abstract
BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with …
Authors
Schmidt AF; Swerdlow DI; Holmes MV; Patel RS; Fairhurst-Hunter Z; Lyall DM; Hartwig FP; Horta BL; Hyppönen E; Power C
Journal
The Lancet Diabetes & Endocrinology, Vol. 5, No. 2, pp. 97–105
Publisher
Elsevier
Publication Date
2 2017
DOI
10.1016/s2213-8587(16)30396-5
ISSN
2213-8587